F.D.A. Approves New Nasal Spray for Migrainesnews2023-03-10T18:37:27+00:00March 10th, 2023|The New York Times|
Start-Up Paradigm Raises $200 Million to Speed Up Drug Trialsnews2023-01-27T10:00:17+00:00January 27th, 2023|The New York Times|
The Only H.I.V. Vaccine in Advanced Trials Has Failed. What Now?news2023-01-18T21:26:06+00:00January 18th, 2023|The New York Times|
FDA Approves, Leqembi, New Treatment for Early Alzheimer’snews2023-01-06T22:58:48+00:00January 6th, 2023|The New York Times|
How Anthony Fauci Quietly Shocked AIDS Activistsnews2022-12-31T14:00:06+00:00December 31st, 2022|The New York Times|
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogennews2022-12-29T19:54:35+00:00December 29th, 2022|The New York Times|
Can a Federally Funded ‘Netflix Model’ Fix the Broken Market for Antibiotics?news2022-12-16T10:00:26+00:00December 16th, 2022|The New York Times|
Alzheimer’s APOE4 Genetic Risk Targeted in Promising Trialnews2022-12-02T21:55:07+00:00December 2nd, 2022|The New York Times|
Alzheimer’s Drug May Benefit Some Patients, New Data Showsnews2022-11-30T00:50:06+00:00November 30th, 2022|The New York Times|
The End of Covid Vaccines at ‘Warp Speed’news2022-11-18T14:02:03+00:00November 18th, 2022|The New York Times|
